Surfactant Therapy for Neonatal Respiratory Distress Syndrome: A Review of Korean Experiences over 17 Years.
10.3346/jkms.2009.24.6.1110
- Author:
Chong Woo BAE
1
;
Won Ho HAHN
Author Information
1. Department of Pediatrics, College of Medicine, Kyunghee University, Seoul, Korea. baecw@khnmc.or.kr
- Publication Type:Multicenter Study ; Review
- Keywords:
Respiratory Distress Syndrome, Newborn;
Premature;
Complications;
Epidemiology;
Mortality;
Pulmonary Surfactants;
Analysis;
Therapeutic Use;
Data Collection
- MeSH:
Birth Weight;
Female;
Gestational Age;
Humans;
Infant, Newborn;
Infant, Premature, Diseases/epidemiology/mortality/pathology/*therapy;
Korea/epidemiology;
Longitudinal Studies;
Pregnancy;
Pulmonary Surfactants/*therapeutic use;
Questionnaires;
Radiography, Thoracic;
Respiratory Distress Syndrome, Newborn/epidemiology/mortality/pathology/*therapy;
Treatment Outcome
- From:Journal of Korean Medical Science
2009;24(6):1110-1118
- CountryRepublic of Korea
- Language:English
-
Abstract:
We undertook a multi-hospital collective study to evaluate outcomes of neonatal respiratory distress syndrome (RDS) patients treated with pulmonary surfactant (PS) over 17 yr in Korea (Group I; 1990/91, Group II; 1996, Group III; 2002, and Group IV; 2007). There were 60 neonates in Group I (16 hospitals), 1,179 in Group II (64), 1,595 in Group III (62), and 1,921 in Group IV (57). We adopted Bomsel's classification to evaluate initial chest radiographic findings, categorized RDS severities, and classified response types to PS therapy. Almost all cases were treated using a single dose in Groups I and II, but 19.5% received multiple-dose therapy in Group IV. In Group IV, Bomsel's stages III and IV composed 62.9% and initial severities of mild, moderate, and severe RDS were 23.0%, 42.0%, and 35.0%. More infants showed good response in Groups II, III, and IV than in Group I (71.7%, 66.8%, and 69.2% vs. 58.3%). Complications and mortality rate were lower in Group IV than in Groups I, II, and III (mortality rate: 14.3% vs. 40.0%, 30.0%, and 18.7%). We conclude that PS therapy in neonates with RDS had a remarkable impact on improving clinical course and outcomes over 17 yr in Korea.
